INCY - Incyte Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
66.59
-1.69 (-2.48%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close68.28
Open68.37
Bid65.00 x 1100
Ask68.50 x 4000
Day's Range66.42 - 68.86
52 Week Range60.23 - 118.32
Volume1,300,230
Avg. Volume1,541,841
Market Cap14.156B
Beta1.78
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • A Look at Sage Therapeutics’ NMDA Receptor Portfolio
    Market Realist12 hours ago

    A Look at Sage Therapeutics’ NMDA Receptor Portfolio

    As discussed earlier, Sage Therapeutics (SAGE) is focused on the development of products for the treatment of life-threatening central nervous system (or CNS) disorders. The products under development include SAGE-718 and SAGE-904.

  • Shire’s Quarterly Revenue Trend
    Market Realistyesterday

    Shire’s Quarterly Revenue Trend

    Biotechnology company Shire (SHPG) reported a 4.6% YoY (year-over-year) rise in revenue to ~$3.9 billion in the second quarter compared to $3.7 billion in the second quarter of 2017.

  • Is Incyte Corporation (NASDAQ:INCY) As Strong As Its Balance Sheet Indicates?
    Simply Wall St.2 days ago

    Is Incyte Corporation (NASDAQ:INCY) As Strong As Its Balance Sheet Indicates?

    Incyte Corporation (NASDAQ:INCY), a large-cap worth US$14.42b, comes to mind for investors seeking a strong and reliable stock investment. Most investors favour these big stocks due to their strong balanceRead More...

  • Zacks3 days ago

    Agenus Receives Milestone Payment of $5 Million from Incyte

    Agenus (AGEN) receives a milestone payment of $5 million from Incyte on the initiation of a phase I study of INCAGN2385.

  • See what the IHS Markit Score report has to say about Incyte Corp.
    Markit7 days ago

    See what the IHS Markit Score report has to say about Incyte Corp.

    Incyte Corp NASDAQ/NGS:INCY

  • Biotech Stock Roundup: GILD's Arthritis Drug Successful in Phase III, PRQR Soars
    Zacks10 days ago

    Biotech Stock Roundup: GILD's Arthritis Drug Successful in Phase III, PRQR Soars

    Pipeline updates and collaborating agreement comprise some of the key developments in the biotech sector this week.

  • Incyte, Foundation Medicine Partner for Companion Diagnostics
    Zacks10 days ago

    Incyte, Foundation Medicine Partner for Companion Diagnostics

    Incyte (INCY) inks an agreement with Foundation Medicine for the development of companion diagnostics (CDx) for Incy's selective FGFR Inhibitor, pemigatinib.

  • Benzinga11 days ago

    The Daily Biotech Pulse: Advaxis Posts Narrower Loss, Endocyte Announces $175M Offering, Leadership Transition At Insulet

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Stocks that hit 52-week highs Sept. 7.) Amgen, Inc. (NASDAQ: AMGN )/p BioSpecifics Technologies ...

  • Benzinga12 days ago

    The Week Ahead In Biotech: Conferences, Clinical Trial Results, Earnings And IPOs

    After recording stellar gains of 4.3 percent in the week ended Aug. 31 to close the month in the green, the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB ) saw a moderation in momentum in the holiday-shortened ...

  • Benzinga15 days ago

    5 Stocks To Have On Your Radar Next Week

    The following stocks are currently in the midst of strong trendsaccording to VantagePoint , an AI charting platform that uses intermarket analysis  and artificial intelligence to predict future price action ...

  • Why Incyte Stock Gained 11% in August
    Motley Fool16 days ago

    Why Incyte Stock Gained 11% in August

    Shares recovered some of their recent losses following encouraging second-quarter results.

  • Why Is Incyte (INCY) Up 12.9% Since Last Earnings Report?
    Zacks23 days ago

    Why Is Incyte (INCY) Up 12.9% Since Last Earnings Report?

    Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Investopedia24 days ago

    3 Stocks That May Lead a Massive Biotech Breakout

    Biotech stocks are hot and have rallied by 13% as measured by the iShares Nasdaq Biotechnology ETF ( IBB) since late May. The recent increase has helped the ETF rise by 14% for the year, beating the S&P 500's gain of 9%. Companies like Celgene Corp. ( CELG), Regeneron Pharmaceuticals Inc. ( REGN) and Incyte Corp. ( INCY) may rise by 10% or more in the coming weeks based on the technical charts, leading the charge higher. The Nasdaq Biotech ETF is breaking out as it rises above a long-term downtrend that has been in place since the summer of 2015.

  • Is Agenus Inc. Stock a Buy?
    Motley Foollast month

    Is Agenus Inc. Stock a Buy?

    Agenus' stock has been ripping higher this week, but that doesn't make it a strong buy.

  • The Latest Recommendations for Incyte
    Market Realistlast month

    The Latest Recommendations for Incyte

    Wall Street analysts expect Incyte (INCY) to report a 17.8% YoY (year-over-year) rise in sales to $1.81 billion in 2018 compared to $1.54 billion in 2017. Incyte is expected to report net adjusted income of $245.1 million in 2018 compared to net adjusted income of -$313.1 million in 2017. Incyte’s stock price has fallen nearly 42.4% over the last 12 months and nearly 26.5% year-to-date in 2018.

  • How Incyte’s Product Portfolio Is Looking in August
    Market Realistlast month

    How Incyte’s Product Portfolio Is Looking in August

    Incyte’s (INCY) product portfolio includes the targeted therapies and immunotherapies for the treatment of oncology and non-oncology diseases. 

  • Gilead paid $510M for drug and just sold it for $3 million
    American City Business Journalslast month

    Gilead paid $510M for drug and just sold it for $3 million

    Momelotinib once looked like a promising treatment for a bone marrow disorder, but after mixed results in late-stage clinical trials, Gilead shelved it. Now it's sold the drug to a Canadian company.

  • Incyte’s Revenue Stream in Q2 2018
    Market Realistlast month

    Incyte’s Revenue Stream in Q2 2018

    Incyte (INCY) reported revenue of $521.5 million in the second quarter, a 59.7% rise YoY (year-over-year) compared to $326.4 million in the second quarter of 2017.

  • A Look at Incyte’s Valuation on August 22
    Market Realistlast month

    A Look at Incyte’s Valuation on August 22

    Incyte (INCY), a biopharmaceutical company, is focused on the discovery, development, and commercialization of various products to cater to unmet medical needs in oncology and the treatment of other diseases.

  • Benzingalast month

    Incyte Has Quietly Risen 13 Percent In The Last Two Weeks, And That Uptrend Looks Like It Will Continue

    Incyte Corporation (NASDAQ: INCY) took it on the chin in April, as the company announced that its Phase 3 study for an experimental combo with Merk & Co., Inc. (NYSE: MRK) had failed to reach its primary endpoint.

  • Here’s How Exelixis Is Financially Positioned Now
    Market Realistlast month

    Here’s How Exelixis Is Financially Positioned Now

    Exelixis (EXEL) generated net revenues of $186.1 million in the second quarter of 2018 compared to $99 million in the second quarter of 2017. In the first half of 2018, Exelixis reported revenues of $399.8 million compared to $179.9 million in the first half of 2017. In the first half of 2018, Exelixis generated revenues of $280.1 million, reflecting ~92% YoY (year-over-year) growth.

  • What’s Ionis Pharmaceuticals’ Valuation after Q2 Results?
    Market Realistlast month

    What’s Ionis Pharmaceuticals’ Valuation after Q2 Results?

    Ionis Pharmaceuticals (IONS), a leading RNA-targeted therapeutics developing company, aims to develop best-in-class drugs for life-threatening diseases. Ionis commercializes the approved products in collaboration with other pharmaceuticals companies. Ionis reported revenues of $118 million in Q2 2018, a 5% increase in year-over-year (or YoY) revenues as compared to the second quarter of 2017.

  • See what the IHS Markit Score report has to say about Incyte Corp.
    Markitlast month

    See what the IHS Markit Score report has to say about Incyte Corp.

    This could indicate that investors who seek to profit from falling equity prices are not currently targeting INCY. Over the last month, growth of ETFs holding INCY is favorable, with net inflows of $19.82 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing.

  • Morningstarlast month

    10 Undervalued Stocks With 'Exponential' Growth Potential

    Of course, it's difficult to predict which technologies will change our world and how long their influence will last. On top of that, it's often a challenge for investors to identify investable opportunities associated with these groundbreaking technologies. The Morningstar Exponential Technologies Index focuses on finding high-growth companies that are in the early stages of developing technologies that are expected to have a broad impact on society and transform how we live and work.

  • This stock sector most often beats analysts’ estimates
    MarketWatch2 months ago

    This stock sector most often beats analysts’ estimates

    Sixty-one of 63 health-care companies have exceeded analysts’ estimates when they reported their most recent results.